Def Leppard guitarist Vivian Campbell missed the band's first concert of 2025 due to his recovery from cancer treatment.

Campbell, the guitarist for Def Leppard, made headlines this week because he missed the band’s first show of 2025 which took ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

Revolution Medicines, Inc. (NASDAQ:RVMD) has been making waves in the biotechnology sector with its innovative approach to ...

For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with ...

EVX-01 is designed with Evaxion’s AI-Immunology™ platform and tailored to target the unique tumor profile and immune characteristics of each individual patient. It engages the patient's immune system ...

Merck (MRK) stock in focus as the company eyes 2025 launch of subcutaneous Keytruda amid a looming patent cliff for its ...

BBO-8520, an investigational oral agent, has been granted fast track designation from the FDA in previously treated KRAS G12C ...

(RTTNews) - Bicycle Therapeutics plc (BCYC), Monday announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) ...

Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory ...

CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases ...